MORPHINE Drug Patent Profile
✉ Email this page to a colleague
When do Morphine patents expire, and when can generic versions of Morphine launch?
Morphine is a drug marketed by Actavis Elizabeth, Anda Repository, Impax Labs Inc, Strides Pharma Intl, Teva Pharms Usa, Upsher Smith Labs, Hikma, Hospira, Hospira Inc, Icu Medical Inc, Intl Medication Sys, Specgx Llc, Watson Labs, Fresenius Kabi Usa, Ani Pharms, Chartwell Molecular, Padagis Us, Pharm Assoc, Rhodes Pharms, Sankalp Lifecare, Tris Pharma Inc, Vistapharm, Winder Labs Llc, Dava Pharms Inc, Dr Reddys Labs Sa, Epic Pharma Llc, Nesher Pharms, Novel Labs Inc, Rising, Sun Pharm Inds Ltd, Sun Pharm Industries, Alkem Labs Ltd, Ingenus Pharms Nj, and Meridian Medcl Techn. and is included in sixty-two NDAs. There are three patents protecting this drug.
The generic ingredient in MORPHINE is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Morphine
A generic version of MORPHINE was approved as morphine sulfate by HOSPIRA on September 30th, 1992.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MORPHINE?
- What are the global sales for MORPHINE?
- What is Average Wholesale Price for MORPHINE?
Summary for MORPHINE
| US Patents: | 0 |
| Applicants: | 34 |
| NDAs: | 62 |
| Drug Prices: | Drug price information for MORPHINE |
| Drug Sales Revenues: | Drug sales revenues for MORPHINE |
| DailyMed Link: | MORPHINE at DailyMed |
US Patents and Regulatory Information for MORPHINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | MORPHINE SULFATE | morphine sulfate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 204223-001 | Oct 30, 2013 | RX | Yes | Yes | 9,072,781 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Pharm Assoc | MORPHINE SULFATE | morphine sulfate | SOLUTION;ORAL | 206573-001 | Nov 14, 2016 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hikma | MORPHINE SULFATE | morphine sulfate | INJECTABLE;INJECTION | 211452-001 | Jan 12, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Teva Pharms Usa | MORPHINE SULFATE | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 202718-005 | Dec 29, 2014 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm Industries | MORPHINE SULFATE | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 205634-002 | Aug 25, 2016 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Strides Pharma Intl | MORPHINE SULFATE | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 075295-002 | Oct 28, 1998 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Winder Labs Llc | MORPHINE SULFATE | morphine sulfate | SOLUTION;ORAL | 211454-001 | Feb 12, 2021 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
